Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed/Oxaliplatin Plus Radiotherapy in Inoperable Esophageal Cancer
NCT01732380Phase 2Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jul 2012
- Primary completion
- Jul 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of raltitrexed and oxaliplatin in esophageal cancer (2 arms), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Progression-Free Survival up to 2 years. Status: unknown.
02
Drugs
raltitrexedoxaliplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT01732380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732380.